B7 + T cells in myeloma: An acquired marker of prior chronic antigen presentation

Leukemia and Lymphoma

Volumn 45, Issue 2, 2004, Pages 363-371

  Brown, Ross ^a   Murray, Allan ^a   Pope, Belinda ^a   Sze, Daniel ^a   Gibson, John ^a   Ho, P Joy ^a   Joshua, Doug ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CD80; Co stimulatory molecules; Multiple myeloma; T cells

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL CULTURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LYMPHOCYTE CLONE; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MONOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PURIFICATION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD45; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MULTIPLE MYELOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; UP-REGULATION;

EID: 0842279717     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001607142     Document Type: Article

References (34)

1. Chai, J.G., Vendetti, S., Amofah, E., Dyson, J. and Lechler, R. (2000) "CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation", Journal of Immunology, 165, 3037-3042.
2. Gimmi, C.D., Freeman, G.J., Gribben, J.G., Gray, G. and Nadler, L.M. (1993) "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation", Proceedings of National Academy of Science of USA, 90, 6586-6590.
3. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J. and Nadler, L.M. (1994) "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumour immunity", Blood, 84, 3261-3283.
4. June, C.H., Bluestone, J.A., Nadler, L.M. and Thompson, C.B. (1994) "The B7 and CD28 receptor families", Immunology Today, 15, 321-331.
5. Linsley, P.S., Clark, E.A. and Ledbetter, J.A. (1990) "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1", Proceedings of National Academy of Science USA, 87, 5031-5035.
6. Linsley, P.S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N.K. and Ledbetter, J.A. (1991) "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation", Journal of Experimental Medicine, 173, 721-730.
7. Schultz, J., Nadler, L. and Gribben, J. (1996) "B7-mediated costimulation and the immune response", Blood Reviews, 10, 111-127.
8. Sotomayor, E.M., Borrello, I., Rattis, F.M., Cuenca, A.G., Abrams, J., Staveley-O'Carroll, K. and Levitsky, H. (2001) "Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression", Blood, 98, 1070-1077.
9. Banchereau, J. and Steinman, R.M. (1998) "Dendritic cells and the control of immunity", Nature, 392, 245-252.
10. Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S. and Bhardwaj, N. (2000) "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", Journal of Experimental Medicine, 191, 423-434.
11. Wojtowicz-Praga, S. (1997) "Reversal of tumor-induced immunosuppression: a new approach to cancer therapy", Journal of Immunotherapy, 20, 165-177.
12. Brown, R.D., Pope, B., Murray, A., Gibson, J., Sze, M.D., Ho, P.J. and Joshua, D. (2001) "Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to upregulate CD80 (B7-1) expression after huCD40LT stimulation due to inhibition by TGFβ and IL-10. Blood, 98, 2992-2998.
13. Wolthers, K.C., Otto, S.A., Kolbach, D.N., van Lier, R.A., Miedema, F. and Meyaard, L. (1996) "Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells", European Journal of Immunology, 26, 1700-1706.
14. Takasaki, Y., Abe, K., Tokano, Y. and Hashimoto, H. (1999) "The expression of LFA-1, JCAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy", Internal Medicine, 38, 175-177.
15. Sabzevari, H., Kantor, J., Jaigirdar, A., Tagaya, Y., Naramura, M., Hodge, J., Bernon, J. and Schlom, J. (2001) "Acquisition of CD80 (B7-1) by T cells", Journal of Immunology, 166, 2505-2513.
16. Chai, J.G., Bartok, I., Scott, D., Dyson, J. and Lechler, R. (1998) "T:T antigen presentation by activated marine CD8+ T cells induces anergy and apoptosis", Journal of Immunology, 160, 3655-3665.
17. Joshua, D.E., Penny, R., Matthews, J.P., Laidlaw, C.R., Gibson, J., Bradstock, K., Wolf, M. and Goldstein, D. (1997) "Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma", British Journal of Haematology, 97, 38-45.
18. Raitakari, M., Brown, R.D., Sze, D., Yuen, E., Barrow, L., Nelson, M., et al. (2000) "T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells", British Journal of Haematology, 110, 203-209.
19. Schlienger, K., Uyemura, K., Jullien, D., Sieling, P.A., Rea, T.H., Linsley, P.S., et al. (1998) "B7-1, but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy", Journal of Immunology, 161, 2407-2413.
20. Behrens, L., Kershensteiner, M., Misgeld, T., Goebels, N., Wekerle, H. and Hohfeld, R. (1998) "Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions", Journal of Immunology, 161, 5943-5951.
21. Lim, S.H. and Bailey-Wood, R. (1999) "Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma", International Journal of Cancer, 83, 215-222.
22. Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., et al. (1999) "Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy", Blood, 94, 673-683.
23. Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., et al. (1999) "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study", Blood, 93, 2411-2419.
24. Ruffini, P.A., Neelapu, S.S., Kwak, L. and Biragyn, A. (2002) "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", Haematologica, 87, 989-1001.
25. Yi, Q., Desikan, R., Barlogie, B. and Munshi, N. (2002) "Optimizing dendritic cell-based immunotherapy in multiple myeloma", British Journal of Haematology, 117, 297-305.
26. Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., et al. (2000) "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects", British Journal of Haematology, 108, 805-816.
27. Jorgensen, T., Gaudernack, G. and Hannestad, K. (1980) "Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315", Scandinavian Journal of Immunology, 11, 29-35.
28. Zeis, M., Frenzke, H., Schmitz, N., Uharek, L. and Steinmann, J. (2002) "Idiotype protein-pulsed dendritic, cells produce strong antimyeloma effects after syngeneic stem cell transplantation in mice", Bone Marrow Transplantation, 29, 213-221.
29. Osterborg, A., Yi, Q., Bergenbrant, S., Holm, G., Lefvert, A.K. and Mellstedt, H. (1995) "Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests", British Journal of Haematology, 89, 110-116.
30. Hwang, I., Huang, J.F., Kishimoto, H., Brunmark, A., Peterson, P.A., Jackson, M.R., et al. (2000) "T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells:, Journal of Experimental Medicine, 191, 1137-1148.
31. Sze, D., Brown, R., Gibson, J., Ho, J., Yang, S., Pelka, G., et al. (2001) "Multiple myeloma idiotypic peptide-cytotoxic T cell interaction constitutes a minimal anti-tumor response", Blood, 98, 652a.
32. Trojan, A., Schultze, J.L., Witzens, M., Vonderheide, R.H., Ladetto, M., Donovan, J.W., et al. (2002) "Immunoglobulin framework-derived peptides function as cytotoxic T cell epitopes commonly expressed in B cell malignancies", Nature Medicine, 6, 667-672.
33. Bogen, B., Schenck, K., Munthe, L.A. and Dembic, Z. (2000) "Deletion of idiotype (Id)-specific T cells in multiple myeloma", Acta Oncolologica, 39, 783-788.
34. Tomkins, M.B., Bull, M.E., Dow, J.L., Ball, J.M., Collisson, E.W., Winslow, B.J., et al. (2002) "Feline immunodeficiency virus infection is characterized by B7+ CTLA4+ T cell apoptosis", Journal of Infectious Diseases, 185, 1077-1093.